Skip to main content

Table 2 Patient data at baseline and after 6-mo study period

From: Effects of co-administration of candesartan with pioglitazone on inflammatory parameters in hypertensive patients with type 2 diabetes mellitus: a preliminary report

N

 

41

39

Dropped out

 

N/A

2

BW(kg)

 

73.24

(2.50)

74.8

(2.29

BMI(kg/m2)

 

26.40

(0.71)

26.95

(0.69)

Blood pressure(SBP/DBP)(mmHg)

 

141

(2.14)/

133

(2.04)*/

85.5

(1.57)

79.3

(1.51)

Laboratory data

     

  HbA1c

(%)

8.32

(0.20)

7.48

(0.17)*

  FPG

(mol/l)

9.72

(0.49)

8.17

(0.37)*

  HMW-ADN

(μg/ml)

4.50

(0.60)

7.99

(0.71)*

  PAl-1

(mg/dl)

32.7

(2.60)

24.1

(1.89)*

  VCAM-1

(mg/dl)

698.9

(27.9)

680.6

(30.15)

  U-8-OHdg

(ng/mg cr)

11.7

(0.62)

11.7

(0.44)

  Hs-CRP

(mg/dl)

0.27

(0.05)

0.19

(0.04)

  1. BMI, Body-mass index; DBP, diastolic blood pressure; SBP, systolic blood pressure; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; HMW-ADN, high molecular weight-adiponectin; Hs-CRP, high sensitivity-Creactive protein; PAI-1, plasminogen activator inhibitor-1; U-8-OHdg, urinary-8-hydroxydeoxygnosine; VCAM-1, vascular cell adhesion molecule-1. Data are expressed as means (sem). or n and %. *P<0.01.